306935-94-4 Usage
Uses
Used in Pharmaceutical Industry:
3-(5-FORMYL-2-FURYL)BENZENESULFONAMIDE is used as a pharmaceutical ingredient for the development of drugs targeting bacterial and fungal infections. Its unique structure, including a furan ring, a benzene ring, and a sulfa group, makes it a promising candidate for creating effective treatments against these infections.
Used in Drug Development and Research:
3-(5-FORMYL-2-FURYL)BENZENESULFONAMIDE is used as a candidate for further drug development and research due to its potential pharmaceutical activity. The formyl group in the molecule plays a crucial role in its effectiveness, and ongoing research may lead to the discovery of new applications and improvements in existing treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 306935-94-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,6,9,3 and 5 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 306935-94:
(8*3)+(7*0)+(6*6)+(5*9)+(4*3)+(3*5)+(2*9)+(1*4)=154
154 % 10 = 4
So 306935-94-4 is a valid CAS Registry Number.
InChI:InChI=1/C11H9NO4S/c12-17(14,15)10-3-1-2-8(6-10)11-5-4-9(7-13)16-11/h1-7H,(H2,12,14,15)
306935-94-4Relevant articles and documents
Inhibitors of HCV NS5B polymerase. Part 1: Evaluation of the southern region of (2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid
Pfefferkorn, Jeffrey A.,Greene, Meredith L.,Nugent, Richard A.,Gross, Rebecca J.,Mitchell, Mark A.,Finzel, Barry C.,Harris, Melissa S.,Wells, Peter A.,Shelly, John A.,Anstadt, Robert A.,Kilkuskie, Robert E.,Kopta, Laurice A.,Schwende, Francis J.
, p. 2481 - 2486 (2007/10/03)
A novel series of nonnucleoside HCV NS5B polymerase inhibitors were prepared from (2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid, a high throughput screening lead. SAR studies combined with structure based drug design focusing on the southern heterobiaryl region of the template led to the synthesis of several potent and orally bioavailable lead compounds. X-ray crystallography studies were also performed to understand the interaction of these inhibitors with HCV NS5B polymerase.